Abstract
This study aimed to assess the efficacy of a new formulation containing melatonin precursors in patients with sleep disorders. Thirty-six individuals were divided into two groups: one receiving the new formulation and the other a placebo, for 30 days. Sleep quality was evaluated using the Pittsburgh Sleep Quality Index (PSQI) questionnaire before and after intervention. It showed significant improvements in sleep quality, including reduced time to fall asleep, fewer nighttime awakenings, and higher overall satisfaction, in the group receiving the new formulation. However, some aspects, such as difficulty staying awake during the day, did not show significant differences. Comparison between groups revealed initial disparities in sleep-related aspects, which narrowed after intervention in the formulation supplement group. These findings suggest that the new formulation may effectively improve sleep quality, emphasizing the need for further research to comprehensively understand its impact on sleep and overall health.

This publication has 13 references indexed in Scilit: